Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction

Area of Science:

• Regenerative Medicine
• Urology
• Cell Therapy

Background:

• Urological dysfunction, particularly impaired detrusor contractility, presents a significant clinical challenge.
• Current treatments for detrusor underactivity have limitations.
• Muscle-derived cells (MDC) possess stem cell characteristics and hold potential for regenerative therapies.

Purpose of the Study:

• To assess the feasibility of muscle-based gene therapy and tissue engineering for urological dysfunction.
• To investigate the therapeutic potential of genetically engineered MDC for impaired detrusor contractility.
• To evaluate the survival, differentiation, and integration of injected MDC in the bladder wall.

Main Methods:

• Highly purified muscle-derived cells (MDC) were genetically engineered to express beta-galactosidase.
• MDC were injected into the bladder walls of severe combined immunodeficient (SCID) mice.
• Injected bladders were analyzed for beta-galactosidase activity, myofiber presence (fast myosin heavy chain isoform), smooth muscle differentiation (alpha-smooth muscle actin), and neuromuscular junction formation (acetylcholine receptors).

Main Results:

• Injected MDC survived within the lower urinary tract of SCID mice.
• Bladder contractility was improved following induced injury in mice treated with MDC.
• Evidence suggested MDC differentiation into smooth muscle and successful innervation into the bladder wall within two weeks post-injection.

Conclusions:

• Muscle-derived cells (MDC) are a feasible cell source for gene therapy and tissue engineering in urology.
• MDC transplantation can restore bladder function by differentiating into smooth muscle and integrating into the bladder's neuromuscular system.
• This approach offers a potential novel therapeutic strategy for urological dysfunction, including impaired detrusor contractility.